by NMS Group | Dec 31, 2019 | 2019, News
Nerviano, 31.12.2019 NMS Group, the leading group providing complete and innovative oncology solution, has announced the merger by incorporation of CLIOSS S.r.l. (Clinical Organization for Strategies & Solotions S.r.l.) into NMS S.r.l. (Nerviano Medical Sciences...
by NMS Group | Dec 13, 2019 | 2019, News
Nerviano, 13.12.2019 Accelera, a leader in preclinical research and a NMS group member, today announced the appointment of Claudio Bernardi as industry representative of the National Expert Committee for the PARERE Network – the EURL ECVAM (the European Union...
by NMS Group | Dec 13, 2019 | 2019, News
Nerviano, 13.12.2019 Dr. Enrico Pesenti, CEO of Accelera-a member of NMS Group, has co-authored the Article entitled “A tumor-in-host DEB-based approach for modeling cachexia and bevacizumab resistance” on the highly respected “Cancer Research” journal Abstract:...
by NMS Group | Dec 10, 2019 | 2019, News
Nerviano, 10.12.2019 A delegation led by Ambassador Li Junhua had visited our NMS Group in Nerviano, Milan on Tuesday morning, December 10th and warmly welcomed by Mr. Andrea Agazzi, Chairman of the Group, Dr. Ying Shao, Chief Executive Officer, and all members of the...
by NMS Group | Nov 27, 2019 | 2019, News
Nerviano, 27.11.2019 Nerviano Medical Sciences, forerunner in oncology drug discovery and development and a NMS group member, today announced the enrollment and dosing of the 1st patient in a phase I First in Human (FIH) study of NMS-293 as a single agent to treat...
by NMS Group | Sep 24, 2019 | 2019, News
Nerviano, 24.09.2019 China BioMed Innovation and Investment Conference (CBIIC) was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) in 2016. As an annual grand conference to promote the communication between...
Welcome and Check out our new motion picture!
Recent Comments